AAV9.LAMP2B gene therapy for Danon disease: from early clinical experience to evolving safety and trial design considerations

References

[1] Boslough M,Taylor M.How ultra-rare is Danon disease? An estimate of prevalence based on multiple data sources.Eur J Heart Fail2026;28:xuag193.282

[2] Yu K,Zhao D.Danon disease: two case reports and literature review.Medicine2026;105:e46993

[3] Cetin H,Rittelmeyer I.The c.65-2A>G splice site mutation is associated with a mild phenotype in Danon disease due to the transcription of normal LAMP2 mRNA.Clin Genet2016;90:366-71

[4] Sugie K,Eura N.A nationwide survey on Danon disease in Japan.Int J Mol Sci2018;19:3507

[5] Del Favero G,Rowland TJ.Danon disease-associated LAMP-2 deficiency drives metabolic signature indicative of mitochondrial aging and fibrosis in cardiac tissue and hiPSC-derived cardiomyocytes.J Clin Med2020;9:2457

[6] Nishino I,Tanji K.Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease).Nature2000;406:906-10

[7] Hashem SI,Divakaruni AS.Impaired mitophagy facilitates mitochondrial damage in Danon disease.J Mol Cell Cardiol2017;108:86-94

[8] Hong KN,Arad M.International consensus on differential diagnosis and management of patients with Danon disease: JACC state-of-the-art review.J Am Coll Cardiol2023;82:1628-47

[9] Manso AM,Nelson BC.Systemic AAV9.LAMP2B injection reverses metabolic and physiologic multiorgan dysfunction in a murine model of Danon disease.Sci Transl Med2020;12:eaax1744

[10] Greenberg B,Adler E.Phase 1 study of AAV9.LAMP2B gene therapy in danon disease.N Engl J Med2025;392:972-83

[11] Johnson V. Danon disease gene therapy yields sustained clinical benefit. CGTlive. Available from: https://www.cgtlive.com/view/danon-disease-gene-therapy-yields-sustained-clinical-benefit [Last accessed on 22 Sep 2026].

[12] Rocket pharmaceuticals provides update on phase 2 clinical trial of RP-A501 for Danon disease. Rocket Pharmaceuticals, Inc. Available from: https://ir.rocketpharma.com/news-releases/news-release-details/rocket-pharmaceuticals-provides-update-phase-2-clinical-trial-rp/ [Last accessed on 22 Sep 2026].

[13] Parajuli S,Flotte TR.Immune Toxicities in AAV Gene Therapy: Overview for Clinicians.Int J Mol Sci2026;27:3196

[14] Rocket pharmaceuticals announces positive clinical safety update from initial three patients treated with RP-A501 Under modified phase 2 protocol for Danon disease. Available from: https://ir.rocketpharma.com/news-releases/news-release-details/rocket-pharmaceuticals-announces-positive-clinical-safety-update [Last accessed on 22 Sep 2026].

[15] Salabarria SM,Coleman KE.Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies.J Clin Invest2024;134

[16] Rocket pharmaceuticals announces FDA has lifted the clinical hold on the pivotal phase 2 trial of RP-A501 for the treatment of danon disease. Rocket Pharmaceuticals, Inc. Available from: https://ir.rocketpharma.com/news-releases/news-release-details/rocket-pharmaceuticals-announces-fda-has-lifted-clinical-hold/ [Last accessed on 22 Sep 2026].

[17] Rocket pharmaceuticals reports second quarter 2026 financial results and highlights recent progress. Rocket Pharmaceuticals, Inc. Available from: https://ir.rocketpharma.com/news-releases/news-release-details/rocket-pharmaceuticals-reports-second-quarter-2026-financial/ [Last accessed on 22 Sep 2026].

[18] Kropf E,Majowicz A,Kuranda K.Complement system response to adeno-associated virus vector gene therapy.Hum Gene Ther2024;35:425-38

[19] Maurizi N,Silver E.Incidence, timing, and clinical significance of adverse immune events after gene replacement therapy: a systematic review and meta-analysis.Mol Ther2026;34:1340-51

[20] Gandaeva L,McKenna WJ.Clinical features of pediatric Danon disease and the importance of early diagnosis.Int J Cardiol2023;389:131189